 |
电子期刊 >> 正文 |
|
摘要：
|
|
目的:评价采用吉非替尼治疗化疗失败的局部晚期或转移性非小细胞肺癌(NSCLC)的疗效及不良反应.方法:42例化疗失败的局部晚期或转移性NSCLC患者予吉非替尼250 mg每日1次口服直至痛情进展或出现不可耐受的不良反应.评价近期疗效、生存期、生活质量及毒副反应.结果:CR 1例、PR 11例、SD 18例、PD 12例,有效率为28.57%、临床受益率为71.43%、中位无疾病进展时间为4个月、中位生存期为10个月、1年生存率为45.23%;生活质量明显改善者占61.90%;药物不良反应多为Ⅰ～Ⅱ度皮疹及
|
|
|
|
基金项目：
|
|
|
|
作者简介：
|
|
|
|
参考文献：
|
|
Kris MG.Natale RB.Herbst RS Efficacy of gefitinib,an inhibitor of the epidermal growth factor receptor tyrosine kinase,in symptomatic patients with non-small cell lung cancer,a randomized trial 2003(16) Fukuoka M.Yano S.Giaccone G Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer 2003(12) Giacconc G.Herbst RS.Manegold C Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer,a phase Ⅲ trial-INTACT 1 2004(5) Hcrbst RS.Giaccone G.Schiller JH Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer,a phase Ⅲ trial-INTACT 2 2004(5) Chanq A.Parikh P.Thonqprasert S Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer,Subset Analysis from the ISEL Study 2006(8) Furukawa M.Nagatomo I.Kumagai T Gefitinib-sensitive EGFR lacking residues 746-750 exhibits hypophosphorylation at tyrosine residue 1045,hypoubi-quitination,and impaired endocytosis 2007(3) Yoshida K.Yatabe Y.Park JY Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small-cell lung cancer 2007(1) Pao W.Miller V.Zakowski M EGF receptor gene mutations are common in lung cancers from " never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib 2004(36) 管忠震.张力.李龙芸.蒋国梁.刘叙仪.储大同.赵洪云.李玮 吉非替尼治疗局部晚期或转移性非小细胞肺癌在中国的临床研究 [期刊论文] -癌症2005(8)
|
|
服务与反馈：
|
|
【文章下载】【加入收藏】
|
|
|
|
|
 |
|
|
 |
|